Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals is positioned for strong financial growth, with an increase in estimated platform revenues attributed to higher research and development spending, leading to a revised total product revenue projection of $5.16 billion by 2026. The company anticipates improved margins and a path to sustainable non-GAAP profitability, primarily driven by nucresiran’s favorable royalty and cost structure in comparison to existing products like AMVUTTRA. Furthermore, the positive outlook is reinforced by increasing physician confidence in subcutaneous dosing, which enhances adherence and persistence in treatment, thereby supporting long-term market expansion and profitability across its diverse therapeutic areas.

Alnylam Pharmaceuticals exhibits a negative outlook primarily due to expectations of slower growth in its rare disease franchise, with projected revenue declining to $500 million to $600 million, significantly impacting overall corporate valuation and earnings potential. Revenue forecasts have been revised downward for key products, including a notable reduction in peak annual revenue projections for nucresiran, now anticipated to reach only $22.9 billion by 2040, alongside further adjustments to TTR revenue estimates that could hinder future business prospects. The company faces substantial risks, including potential commercial uptake challenges for its therapies, increased competition limiting revenue growth, and a protracted path to profitability, all of which could further pressurize its financial metrics and undermine investor confidence.